Posted by Michael Wonder on 06 Mar 2026
HLS Therapeutics announces Nilemdo (bempedoic acid) is now available in Canada for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease
5 March 2026 - HLS Therapeutics today announced the commercial launch of Nilemdo (bempedoic acid) in Canada. Nilemdo is now available by prescription nationally.
HLS in licensed the exclusive rights to Nilemdo and Nexlizet (bempedoic acid and ezetimibe) for the Canadian market from Esperion Therapeutics in May 2025.
